O-GLCNACASE (OGA) INHIBITOR COMBINATION THERAPY

The present invention provides methods of slowing progression of, treating, and/or preventing a disease characterized by amyloid beta deposits and/or a disease characterized by amyloid beta deposits and aberrant tau aggregation. Such methods comprise administering to a patient in need of such treatm...

Full description

Saved in:
Bibliographic Details
Main Authors NUTHALL, Hugh N, FLEISHER, Adam S, BIGLAN, Kevin, MERGOTT, Dustin James
Format Patent
LanguageEnglish
French
German
Published 28.08.2024
Subjects
CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:The present invention provides methods of slowing progression of, treating, and/or preventing a disease characterized by amyloid beta deposits and/or a disease characterized by amyloid beta deposits and aberrant tau aggregation. Such methods comprise administering to a patient in need of such treatment an effective amount of an anti-N3pG Aβ antibody and an effective amount of an OGA inhibitor.
Bibliography:Application Number: EP20220813018